Anti-PEc: Development of a novel monoclonal antibody against prostate cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.An anti-Ec peptide (PEc) monoclonal antibody (MAb) effectively reduced prostate cancer progression, including proliferation and metastasis, with no observed toxicity in preclinical models.
Area Of Science
- Oncology
- Immunotherapy
- Molecular Biology
Background
- The Ec peptide (PEc), part of the IGF-1Ec isoform, promotes prostate cancer progression by enhancing proliferation, metastasis, and tumor repair.
- A novel anti-PEc monoclonal antibody (MAb) was developed to target this pathway.
Purpose Of The Study
- To evaluate the efficacy of the anti-PEc MAb in inhibiting prostate cancer growth and metastasis.
- To assess the safety and potential side effects of the anti-PEc MAb treatment.
Main Methods
- In vitro studies using prostate cancer cell lines (overexpressing or silencing PEc) and non-cancerous cell lines.
- In vivo studies using SCID mice xenograft models of prostate cancer.
- Assessment of proliferation, migration, invasion, cell cycle, immune response, stem cell mobilization, tissue distribution, and toxicity.
Main Results
- Anti-PEc MAb significantly decreased prostate cancer cell proliferation, migration, and invasion (p < 0.0005).
- In vivo, anti-PEc MAb reduced tumor size and metastasis rate (p < 0.0005) by reversing the mesenchymal phenotype and inhibiting stem cell mobilization.
- Treatment showed tumor specificity and no observable toxicity in mice.
Conclusions
- Targeting PEc with the anti-PEc MAb demonstrates significant therapeutic potential for prostate cancer.
- This approach may offer considerable clinical benefit for patients with prostate cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
